The United States Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) (LSE: GSK)(NYSE: GSK) Nucala (mepolizumab) intended for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease, it was reported on Friday.
This is the first new treatment to be approved for HES patients in around 14 years. The product was assessed in a randomised double-blind, multicentre, placebo-controlled trial in 108 patients with HES. The side effects of the product in HES patients include upper respiratory tract infection and pain in extremities (such as the hands, legs and feet).
The US FDA approval is being granted to GlaxoSmithKline of Research Triangle Park, North Carolina.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT